BOOST 3 NEWS AND UPDATES

- Has your site completed the Milestone 1 tasks yet? We will be reaching out to each site soon for an update on your progress on pre-study tasks. Need help? Our team is here to support you, so e-mail us anytime!
- MOP released – download your copy from the SIREN website
- New SIREN cIRB SOP posted

SAEM CCC NETWORK MEETING

Please join us for an informal SIREN/NETT Investigators get-together at the Society for Academic Emergency Medicine (SAEM) meeting.

Thank you for your contributions to SIREN and NETT. In addition to a chance to socialize we will briefly review:

- The continuing evolution from NETT to SIREN,
- The launch of BOOST3
- Status of recently completed NETT trials
- Status of the network’s ongoing, upcoming, and proposed trials including HOBIT, ICECAP and HATTRIC.

Come, have a drink, talk research, mingle. Light refreshments will be provided

REQUEST FROM THE CCC

Subject line: Study name: Your site name – nature of your email (briefly in a few words).
Additionally, including a signature with a telephone number at the bottom of your email is very useful.

-Thanks from the SIREN CCC team

PS – this is a good rule of thumb to follow when e-mailing our site as well. Communications will only need to increase as we move forward with network studies, so please be diligent about clearly identifying these important bits of info so we can keep communications as helpful and efficient as possible.
WORKGROUP RUNDOWN

Wondering if you’re workgroup has started yet? Here’s the breakdown of the groups already meeting the ones still to come.

**Meeting currently:**
- EMS WG Update (3rd Wednesday of the month, 4-5pm EDT)
- HSP WG Update (2nd Thursday of the month 1-2pm EDT)
- EDC WG Update (4th Thursday of the month 12-1pm EDT)
- Cardiovascular Emergencies WG (3rd Wednesday of the month 1-2pm EDT)
- Trauma WG (2nd Tuesday of the month 4-5pm EDT)

**To be convened:**
- Intensivist Investigators
- Outcomes
- Registry based randomized trials
- Training and mentoring

ONGOING TRIALS

- HOBIT
  - Enrollment: 19 subjects (Goal: 200) **Kudos Duke on your enrollment last week!**
    - Did you register for the HOBIT Virtual meeting? [Bit.ly/HOBITmeeting2019](http://Bit.ly/HOBITmeeting2019)
    - Please indicate which session you will be attending when you register: June 11th from 11:00am – 12:30pm; or June 13th from 3:00pm – 4:30pm.

POTENTIAL STUDY: **KETOSIS - KETOGENIC EMERGENCY TREATMENT OF STATUS EPILEPTICUS IN SIREN**

This is a proposal for a phase II multicenter, double-blind, placebo-controlled, restricted Bayesian response adaptive randomization clinical trial designed to determine the ketogenic formula specifications needed to safely induce ketonemia ($\geq 1$ mmol/L blood $\beta$-hydroxybutyrate) within 24 hours in patients with established refractory status epilepticus (requiring general anesthesia to suppress ongoing status epilepticus), as an adjunct to standard medical care.

The primary objective is to determine the most effective ketogenic enteral formula ratio needed to induce ketonemia ($\beta$HB $\geq 1$ mmol/L) within 24 hours of initiation in the setting of established refractory status epilepticus, while avoiding intervention-limiting metabolic acidosis.

April’s Journal Club covered an article on the Ketogenic Diet. Missed it? [Catch up here](http://Catch up here).
POTENTIAL STUDY: EMS POST RESUSCITATION CARE STUDY

This study is still in development. The EMS work group is planning to reach out to SIREN sites in the near future with a small survey to understand current EMS practices around post resuscitative care for out of hospital cardiac arrest.

ED INNOVATION NIDA CLINICAL TRIAL

PLEASE NOTE THIS IS NOT A SIREN NETWORK TRIAL. The study PI is reaching out to SIREN sites to solicit for potential sites. Below is a synopsis, and included with this newsletter are additional information documents from the study PI.

This study will recruit, train and provide resources to 30 Emergency Department (ED) sites throughout the U.S. to implement ED-initiated buprenorphine (BUP) for patients presenting with untreated opioid use disorder (OUD). A pragmatic randomized clinical trial (RCT) comparing the effectiveness of sublingual buprenorphine (SL-BUP) versus a 7-day extended-release formulation of buprenorphine (XR-BUP) in 2000 patients with untreated OUD will be conducted in sites achieving competence (e.g. demonstrating ability to enroll patients with OUD and adhere to protocols for administering both formulations of buprenorphine). The primary outcome will be engagement in formal addiction treatment within 7-days post ED visit. Engagement in formal addiction treatment on the 30th day post randomization and cost effectiveness will also be studied.